Literature DB >> 19061137

First human treatment of resistant neoplastic meningitis by intrathecal administration of MTX plus (125)IUdR.

C Rebischung1, D Hoffmann, L Stefani, M D Desruet, K Wang, S J Adelstein, X Artignan, F Vincent, A S Gauchez, H Zhang, D Fagret, J Vuillez, A I Kassis, J Balosso.   

Abstract

PURPOSE: Neoplastic meningitis is often the final outcome of disseminated cancer and is rapidly lethal. Its limited treatment relies on systemic or intrathecal chemotherapy with methotrexate (MTX) or thiotepa. When 5-iodo-2'-deoxyuridine labeled with (125)I ((125)IUdR) is incorporated into the DNA of mitotic tumor cells, the Auger electrons emitted during iodine decay are highly cytotoxic. The radiotherapeutic efficacy of (125)IUdR administered intrathecally has also been established in animals bearing spinal cord tumors, and MTX is known to potentiate the response. This approach has not been tested in the clinic.
METHODS: A 44-year-old woman, with locally advanced pancreatic cancer, was treated for three years with complete systemic remission, but then relapsed with cytologically proven neoplastic meningitis. The patient was given four successive intrathecal injections of MTX (10 mg) every 12 h and, with the fourth dose, 1850 MBq (125)IUdR, followed by four additional MTX doses. The response was monitored by cytology and CA19.9 (carbohydrate antigen 19.9) levels in the cerebrospinal fluid (CSF) as well as by clinical status of the patient.
RESULTS: The follow-up of cytology and CA19.9 levels in the CSF showed dramatic improvement within 26 days followed by a biological relapse on Day +36. There was no evidence of local central nervous system toxicity. Three months later, neoplastic meningitis recurred and meningeal tumor infiltration was observed on magnetic resonance imaging. Six months after MTX-(125)IUdR treatment, the patient died.
CONCLUSION: (125)IUdR treatment proved to be feasible without acute neurological toxicity and seemed to have produced a biological response. This attempt provides the basis for designing prospective clinical trials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19061137     DOI: 10.1080/09553000802395535

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  19 in total

1.  Effect of distance between decaying (125)I and DNA on Auger-electron induced double-strand break yield.

Authors:  Pichumani Balagurumoorthy; Xiang Xu; Ketai Wang; S James Adelstein; Amin I Kassis
Journal:  Int J Radiat Biol       Date:  2012-07-24       Impact factor: 2.694

2.  Molecular and cellular radiobiological effects of Auger emitting radionuclides.

Authors:  Amin I Kassis
Journal:  Radiat Prot Dosimetry       Date:  2010-11-24       Impact factor: 0.972

3.  A model for optimizing delivery of targeted radionuclide therapies into resection cavity margins for the treatment of primary brain cancers.

Authors:  Raghu Raghavan; Roger W Howell; Michael R Zalutsky
Journal:  Biomed Phys Eng Express       Date:  2017-05-05

4.  Correlation between energy deposition and molecular damage from Auger electrons: A case study of ultra-low energy (5-18 eV) electron interactions with DNA.

Authors:  Mohammad Rezaee; Darel J Hunting; Léon Sanche
Journal:  Med Phys       Date:  2014-07       Impact factor: 4.071

Review 5.  Biology and therapy of neoplastic meningitis.

Authors:  Aaron G Mammoser; Morris D Groves
Journal:  Curr Oncol Rep       Date:  2010-01       Impact factor: 5.075

6.  Phase I trial to evaluate the tumor and normal tissue uptake, radiation dosimetry and safety of (111)In-DTPA-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer.

Authors:  Katherine A Vallis; Raymond M Reilly; Deborah Scollard; Pat Merante; Anthony Brade; Sobi Velauthapillai; Curtis Caldwell; Ida Chan; Marc Freeman; Gina Lockwood; Naomi A Miller; Bart Cornelissen; Jennifer Petronis; Kathryn Sabate
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-03-20

Review 7.  Auger: The future of precision medicine.

Authors:  Giacomo Pirovano; Thomas C Wilson; Thomas Reiner
Journal:  Nucl Med Biol       Date:  2021-03-19       Impact factor: 2.408

8.  In Vitro Evaluation of No-Carrier-Added Radiolabeled Cisplatin ([189, 191Pt]cisplatin) Emitting Auger Electrons.

Authors:  Honoka Obata; Atsushi B Tsuji; Hitomi Sudo; Aya Sugyo; Katsuyuki Minegishi; Kotaro Nagatsu; Mikako Ogawa; Ming-Rong Zhang
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

9.  Validation of the plasmid study to relate DNA damaging effects of radionuclides to those from external beam radiotherapy.

Authors:  Elise Verger; Jordan Cheng; Vittorio de Santis; Madeleine Iafrate; Jessica A Jackson; Cinzia Imberti; Gilbert O Fruhwirth; Philip J Blower; Michelle T Ma; Daniel R Burnham; Samantha Y A Terry
Journal:  Nucl Med Biol       Date:  2021-06-15       Impact factor: 2.408

10.  PARP-Targeted Auger Therapy in p53 Mutant Colon Cancer Xenograft Mouse Models.

Authors:  Thomas Wilson; Giacomo Pirovano; Gu Xiao; Zachary Samuels; Sheryl Roberts; Tara Viray; Navjot Guru; Pat Zanzonico; Marc Gollub; Naga Vara Kishore Pillarsetty; Thomas Reiner; Jill Bargonetti
Journal:  Mol Pharm       Date:  2021-07-28       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.